查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1888722

白血病治療市場規模、佔有率和趨勢分析報告：按白血病類型、治療類型、分銷管道、地區和細分市場預測（2025-2033 年）

Leukemia Therapeutics Market Size, Share & Trends Analysis Report By Type Of Leukemia (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), By Treatment Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

白血病治療市場摘要

2024年全球白血病治療市場規模估計為189億美元，預計2033年將達到360.2億美元。

預計從 2025 年到 2033 年，該市場將以 7.43% 的複合年成長率成長。這一市場擴張是由全球各年齡層急性白血病和慢性白血病盛行率的上升所驅動的。

精準腫瘤學的日益普及使得根據基因和分子特徵制定個人化治療方案成為可能，從而改善了患者的預後。診斷技術的進步提高了早期檢測率，進而促進了治療啟動率的提升。標靶治療和免疫療法的藥物創新正在加速其臨床應用，並改變治療標準。例如，根據2025年4月發表在醫學期刊《前沿醫學》（Frontiers in Medicine）上的《全球疾病負擔研究》，預計2021年新增白血病病例數將達到約461,422.7例，2031年將達到約509,737.3例。此外，預計死亡人數將從2021年的約320,283.6例增加到2031年的344,694.3例。同時，同期傷殘調整壽命年（DALYs）從10,982,836.2下降到10,785,356.1。

隨著存活率的提高，需要長期持續治療的患者群體不斷擴大。在積極的臨床試驗支持下，強勁的研發動能正推動著療效更佳的新治療方法的問世。聯合治療的商業性化應用進一步提升了處方量，並提高了治療價值。

分子標靶藥物的快速應用徹底改變了急性骨髓性白血病(AML)、慢性淋巴性白血病(CLL) 和急性淋巴性白血病(ALL) 的治療策略，實現了高緩解率和可控的安全性。激酶抑制劑、BCL-2 抑制劑和單株抗體的持續進展正在推動治療策略從傳統化療轉向其他療法。 CAR-T 療法因其能夠使復發或難治性疾病患者獲得持久緩解而日益受到關注。例如，2025 年 3 月，《血液學治療進展》雜誌報告了一項 I 期臨床試驗，其中 10 名接受抗 CLL-1 CAR-T 治療的 AML 患者中有 7 名達到完全緩解 (CR) 或伴不完全血小板浸潤的完全緩解 (CRi)。這 6 名患者隨後均接受了幹細胞移植，並在追蹤時仍存活。同時，在另一項試驗中，接受抗CD38 CAR-T治療的6名患者中有3名達到完全緩解，僅出現1-2級細胞激素釋放症候群（CRS），未發生免疫相關神經病變症候群（ICANS）。幹細胞移植的普及、口服療法的廣泛應用以及積極的擴大策略正在推動市場的長期成長。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 白血病治療市場變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 白血病治療市場：依白血病類型分類的業務分析

  • 按白血病類型分類的市場佔有率（2024 年和 2033 年）
  • 白血病市場規模、預測和趨勢分析（按類型分類）（2021-2033 年）
  • 慢性骨髓性白血病（CML）
  • 慢性淋巴性白血病（CLL）
  • 急性淋巴性白血病（ALL）
  • 急性骨髓性白血病（AML）
  • 其他

第5章 白血病治療市場：依治療類型分類的業務分析

  • 按治療類型分類的市場佔有率（2024 年和 2033 年）
  • 按治療類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他

第6章 白血病治療市場：依通路分類的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院藥房
  • 零售藥房
  • 其他

第7章 白血病治療市場：區域估算與趨勢分析

  • 區域市場佔有率分析（2024 年和 2033 年）
  • 區域市場概覽
  • 區域市場規模及預測趨勢分析（2021-2033）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Pfizer Inc.
    • Novartis
    • Lupin Ltd.
    • Amgen Inc.
    • AbbVie
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche
    • Takeda Pharmaceutical Co Ltd
    • Sanofi/Genzyme Corporation
Product Code: GVR-4-68040-809-7

Leukemia Therapeutics Market Summary

The global leukemia therapeutics market size was estimated at USD 18.90 billion in 2024 and is projected to reach USD 36.02 billion by 2033, growing at a CAGR of 7.43% from 2025 to 2033. The market is expanding due to a rising global prevalence of acute and chronic leukemia across all age groups.

The growing adoption of precision oncology is enabling treatments tailored to genetic and molecular profiles, thereby improving patient outcomes. Advancements in diagnostic technologies are enabling earlier detection, which supports higher rates of treatment initiation. Pharmaceutical innovation in targeted therapies and immunotherapies is accelerating clinical adoption and shifting treatment standards. For instance, in April 2025, Frontiers in Medicine published a global burden study which reported that in 2021, there were approximately 461,422.7 leukemia incident cases, projected to reach 509,737.3 by 2031, and around 320,283.6 deaths in 2021 expected to rise to 344,694.3 by 2031, while DALYs declined from 10,982,836.2 to 10,785,356.1 during the same period.

Increasing survival rates are creating a larger population requiring long-term and sequential therapy. Strong R&D momentum supported by active clinical trials is introducing new therapeutic classes with improved efficacy. The commercial availability of combination regimens is further driving prescription volume and increasing therapy value.

The rapid penetration of targeted small-molecule drugs is transforming treatment strategies for AML, CLL, and ALL, delivering high response rates with manageable safety profiles. Continuous progress in kinase inhibitors, BCL-2 inhibitors, and monoclonal antibodies is driving a shift away from traditional chemotherapy. CAR-T therapies are gaining adoption due to their ability to achieve durable remission in patients with relapsed or refractory disease. For instance, in March 2025, Therapeutic Advances in Hematology reported a phase I trial in which 7 of 10 AML patients treated with anti-CLL-1 CAR-T achieved complete remission or CRi. All six who later underwent stem cell transplantation were alive at follow-up. At the same time, another trial showed three complete remissions among six patients receiving anti-CD38 CAR-T, with only grade 1-2 CRS and no ICANS events. Growing access to stem cell transplantation, wider use of oral regimens, and active label expansion strategies are strengthening long-term market growth.

Global Leukemia Therapeutics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global leukemia therapeutics market report based on type of leukemia, treatment type, distribution channel, and region:

  • Type of Leukemia Outlook (Revenue, USD Million, 2021 - 2033)
  • Chronic Myeloid Leukemia (CML)
  • Chronic Lymphocytic Leukemia (CLL)
  • Acute Lymphocytic Leukemia (ALL)
  • Acute Myeloid Leukemia (AML)
  • Others
  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others
  • Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type of Leukemia
    • 1.2.2. Treatment Type
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Leukemia Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Leukemia Therapeutics Market: Type of Leukemia Business Analysis

  • 4.1. Type of Leukemia Market Share, 2024 & 2033
  • 4.2. Type of Leukemia Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type of Leukemia, 2021 to 2033 (USD Million)
  • 4.4. Chronic Myeloid Leukemia (CML)
    • 4.4.1. Chronic Myeloid Leukemia (CML) Market, 2021 - 2033 (USD Million)
  • 4.5. Chronic Lymphocytic Leukemia (CLL)
    • 4.5.1. Chronic Lymphocytic Leukemia (CLL) Market, 2021 - 2033 (USD Million)
  • 4.6. Acute Lymphocytic Leukemia (ALL)
    • 4.6.1. Acute Lymphocytic Leukemia (ALL) Market, 2021 - 2033 (USD Million)
  • 4.7. Acute Myeloid Leukemia (AML)
    • 4.7.1. Acute Myeloid Leukemia (AML) Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Leukemia Therapeutics Market: Treatment Type Business Analysis

  • 5.1. Treatment Type Market Share, 2024 & 2033
  • 5.2. Treatment Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by treatment type, 2021 to 2033 (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Leukemia Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Leukemia Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Leukemia Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Treatment Type Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Treatment Type Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Treatment Type Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Treatment Type Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Treatment Type Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Treatment Type Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Treatment Type Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Treatment Type Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Treatment Type Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Treatment Type Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Treatment Type Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Treatment Type Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Treatment Type Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Treatment Type Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Treatment Type Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Treatment Type Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Treatment Type Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Treatment Type Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Treatment Type Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Treatment Type Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Treatment Type Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Treatment Type Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Treatment Type Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Leukemia Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Pfizer Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Novartis
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Lupin Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Amgen Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. AbbVie
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Johnson & Johnson Services, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Bristol-Myers Squibb
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Takeda Pharmaceutical Co Ltd
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Sanofi/ Genzyme Corporation
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global leukemia therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 5 Global leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 6 Global leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America leukemia therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 9 North America leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 10 North America leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 12 U.S. leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 13 U.S. leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 15 Canada leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 16 Canada leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 18 Mexico leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 19 Mexico leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe leukemia therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 22 Europe leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 23 Europe leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 25 UK leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 26 UK leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 28 Germany leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 29 Germany leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 31 France leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 32 France leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 34 Italy leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 35 Italy leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 37 Spain leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 38 Spain leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 40 Norway leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 41 Norway leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 43 Denmark leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 44 Denmark leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 46 Sweden leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 47 Sweden leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific leukemia therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Million)
  • Table 53 Japan leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 54 Japan leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 55 Japan leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 China leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 57 China leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 58 China leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 India leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 60 India leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 61 India leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Australia leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 63 Australia leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 64 Australia leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 South Korea leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 66 South Korea leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 67 South Korea leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 68 Thailand leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 69 Thailand leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 70 Thailand leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71 Latin America leukemia therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 72 Latin America leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 73 Latin America leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 74 Latin America leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 Brazil leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 76 Brazil leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 77 Brazil leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 78 Argentina leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 79 Argentina leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 80 Argentina leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa Leukemia therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 84 Middle East & Africa leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 85 South Africa leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 86 South Africa leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 87 South Africa leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 90 Saudi Arabia leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 91 UAE leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 92 UAE leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 93 UAE leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 94 Kuwait leukemia therapeutics market, by type of leukemia, 2021 - 2033 (USD Million)
  • Table 95 Kuwait leukemia therapeutics market, by treatment type, 2021 - 2033 (USD Million)
  • Table 96 Kuwait leukemia therapeutics market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Leukemia therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Leukemia therapeutics market dynamics
  • Fig. 12 Leukemia therapeutics market: Porter's five forces analysis
  • Fig. 13 Leukemia therapeutics market: PESTLE analysis
  • Fig. 14 Type of Leukemia market, 2021 - 2033 (USD Million)
  • Fig. 15 Chronic Myeloid Leukemia (CML) market, 2021 - 2033 (USD Million)
  • Fig. 16 Chronic Lymphocytic Leukemia (CLL) market, 2021 - 2033 (USD Million)
  • Fig. 17 Acute Lymphocytic Leukemia (ALL) market, 2021 - 2033 (USD Million)
  • Fig. 18 Acute Myeloid Leukemia (AML) market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Treatment Type market, 2021 - 2033 (USD Million)
  • Fig. 21 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 22 Targeted Therapy market, 2021 - 2033 (USD Million)
  • Fig. 23 Immunotherapy market, 2021 - 2033 (USD Million)
  • Fig. 24 Others market, 2021 - 2033 (USD Million)
  • Fig. 25 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 26 Hospital Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 27 Retail Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Leukemia therapeutics market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 38 Europe leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 55 Asia Pacific leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 68 Latin America leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 73 MEA leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait leukemia therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework